1. Heteromeric GABAAreceptor structures in positively-modulated active states
- Author
-
Mark S.P. Sansom, Trevor G. Smart, Zhaoyang Sun, Els Pardon, Gianni Klesse, Sreenivas Chavali, Saad Hannan, J.M. Diprose, S. Masiulis, Luigi De Colibus, Abhay Kotecha, Shanlin Rao, Paul S. Miller, Brandon Frenz, Juha T. Huiskonen, Stephen J. Tucker, Frank DiMaio, Suzanne Scott, Tomas Malinauskas, Alistair Siebert, Robert Esnouf, Radu Aricescu, Sai Li, Jan Steyaert, and M. Madan Babu
- Subjects
0303 health sciences ,Allosteric modulator ,GABAA receptor ,medicine.drug_class ,Allosteric regulation ,Bretazenil ,Anxiolytic ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,Flumazenil ,medicine ,Biophysics ,Receptor ,030217 neurology & neurosurgery ,Ion channel ,030304 developmental biology ,medicine.drug - Abstract
Type-A γ-aminobutyric acid (GABAA) receptors are pentameric ligand-gated ion channels (pLGICs), typically consisting of α/β/γ subunit combinations. They are the principal mediators of inhibitory neurotransmission throughout the central nervous system and targets of major clinical drugs, such as benzodiazepines (BZDs) used to treat epilepsy, insomnia, anxiety, panic disorder and muscle spasm. However, the structures of heteromeric receptors and the molecular basis of BZD operation remain unknown. Here we report the cryo-EM structure of a human α1β3γ2 GABAAR in complex with GABA and a nanobody that acts as a novel positive allosteric modulator (PAM). The receptor subunits assume a unified quaternary activated conformation around an open pore. We also present crystal structures of engineered α5 and α5γ2 GABAAR constructs, revealing the interfacial site for allosteric modulation by BZDs, including the binding modes and the conformational impact of the potent anxiolytic and partial PAM, bretazenil, and the BZD antagonist, flumazenil. These findings provide the foundation for understanding the mechanistic basis of GABAAR activation.
- Published
- 2018